NCT06498635 2026-03-18
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
10 trialsNCT04267848 2026-03-17
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07447440 2026-03-11
RESOLBE
Clinica Universidad de Navarra, Universidad de Navarra
Recruiting
NCT05640999 2026-03-10
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT06249880 2026-03-09
Pediatric Normative Markerless Movement Analysis
MultiCare Health System Research Institute
Recruiting
NCT05812807 2026-03-04
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06896370 2026-02-25
An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori
Fudan University
Recruiting
NCT06647953 2026-02-24
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Children's Oncology Group
Phase 3 Recruiting
NCT06192719 2026-02-18
EULAT
Centre Paul Strauss
Recruiting
NCT05504681 2026-02-17
Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
Baptist Health South Florida
Recruiting